Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3341-0.0332 (-9.04%)
At close: 04:00PM EST
0.3300 -0.00 (-1.23%)
After hours: 07:54PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3673
Open0.3600
Bid0.3341 x 900
Ask0.3400 x 1400
Day's Range0.3202 - 0.3600
52 Week Range0.3202 - 2.9950
Volume3,420,203
Avg. Volume4,529,021
Market Cap61.065M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-0.7690
Earnings DateMar 10, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • GlobeNewswire

    Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DUBLIN, Ireland and CHICAGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 1,800,000 ordinary shares of Iterum Therapeutics and 500,000 restricted share units

  • Simply Wall St.

    Is Iterum Therapeutics (NASDAQ:ITRM) Weighed On By Its Debt Load?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • GlobeNewswire

    Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer

    DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical developme

Advertisement
Advertisement